[ad_1]
392 new cases in Vienna
© WHAT
In Austria, 1,131 new corona virus infections had been reported within 24 hours on Friday morning. That was 78 less than the previous day’s record, when 1,209 positive tests were recorded. The number of active cases rose to the five-digit range with 10,307 affected, after 9,930 on Thursday. Four more deaths mean 842 people who have died so far. The number of hospitalized patients remained stable with 508 patients, 103 of them intensive.
There were 392 new cases in Vienna, 223 in Lower Austria and 163 in Upper Austria. With 116 new cases, Tirol also had three-digit case numbers; less in Styria (90), Salzburg (58), Vorarlberg (39), Carinthia (27) and Burgenland (23). On average, during the past seven days, there were 973 new infections each day; the day before the seven-day incidence was 910. As of Thursday (9.30am) there were 53,188 positive test results in Austria. 42,039 affected people have been recovered.
Contrary to initial media fears, the crown traffic light remained orange in all districts even after the commission meeting on Thursday. Health Minister Rudolf Anschober (Greens) wants to explain why this is so with experts on Friday. Initially, it was feared that traffic lights would turn red in four districts.
The crisis team meeting is also eagerly awaited, for which Vienna Councilor for Health Peter Hacker (SPÖ) has announced his personal participation. He wanted to clear up misunderstandings after it was first announced Thursday that Vienna no longer wanted to attend staff meetings.
Meanwhile, the development of a possible Covid-19 drug with antibodies from the blood plasma of recovered people, also from Austria, is taking a decisive step. In the phase III clinical study, safety, tolerability and efficacy will now be tested in patients, the pharmaceutical company Takeda in Austria announced on Friday. The product is intended for the treatment of adult patients in hospitals who are at serious risk of complications.
At the end of June, the clinical material manufacturing process was started on the basis of a platform tested at Takeda’s production site in Vienna. The process usually takes on average about a year to start production. The Vienna site now completed the first drugs for the clinical study in less than two months after the process was implemented. “The project is of global significance in terms of health policy. With our experience at Takeda’s Vienna location, we are making a significant contribution to development,” said Thomas Kreil, Director of Global Pathogen Safety at Takeda.
[ad_2]
